Investment Q&A

Q: Would these companies provide a good entry point, currently? It appears that they also seem to investigate respiratory viral treatments.
Thank you, Team!

Q: BHC has dropped after earnings. How does the future look for this company? I have a 5% position and am still up 10%. Is it worth holding? Thanks!

Q: Hi,

BHC will be reporting in about 7 days or so , if I am not mistaken.

May I please get your opinion on this stock.

Thanks,

Q: How do you think on BHC's today's earnings, is this company in the right path to turnaround? Would you start a position on it today? Thanks!

Q: What do you think of Citron's take on Bausch Health? The link is here: https://citronresearch.com/bausch-health-the-textbook-turnaround/

Q: we have seen this stock performing better. Can you comment please

Q: Hello Peter,
There have been many short sellers in the last few years in health care and now in Cannabis stocks. At this point, time will tell on Aphria, but for others like Valeant etc the short sellers were correct. I find it interesting that the brokerage firms, and analyst that covered these companies gave high marks and all of a sudden with a short report, they either revised their price targets or put out a release that the stock is under review rather than defend their own analysis. I am starting to question the analysis that is done by Canadian firms and their ratings. How is it that the short sellers are able to find things that the analysts covering these companies have not managed to even come across? Can you please comment as this is getting ridiculous when analysts and BNN Guests talk highly of companies and than we find out the shortfalls in these companies. Where is the accountability on these analysts and brokerage firms that put out good reports? Thanks very much

Q: I am aware that these companies have high debt levels. However, would you view any one of them investable? Or would there be similar companies with better growth prospects?
Thanks for your input!

Q: Is this a good entry point into BHC and ARE?

Q: Hi Team,

What are your thoughts on this company and its future prospects?

Thanks

Q: Hi folks, please get opinion on Q results for Bausch (formerly Valeant). Stock rallied on raised guidance but has since sold off. Thanks as always, JB

Q: My first question on Points (Peter would know this well as it used to be in the Sprott Growth Fund) and VRX (Valiant) are two stocks that seem to have a lot of momentum for the last little bit. Do you think that they would be too risky to add to a portfolio - I am medium to high risk. Always appreciating your great service. Thanks Dennis

Q: What did you think of the latest quarter? With some lawsuit issues being resolved and debt reduction underway is it time to take a small position? What’s the valuation look like and debt levels? Thanks

Q: stock showing strong upward trend as well as what seems to be encouraging news your opinion going forward

Q: Would this be a good time to take a position in this company based on current fundamentals?

Q: Good morning,
Would you buy VRX , now at $28.30 with a P/E of 5.6 (this from the Nat. Post) or are there still too many problems with this company.
Thank you,
HD

Q: What is your evaluation of this company moving forward.

Q: Greetings 5i,

VRX seems to have rallied since it reported. Mgt looks to be doing a good job in reducing debt and providing transparency. They also offered notes I believe mid November reducing near term debt. I know you are cautious re: VRX however what additionally would be needed to endorse this company? It seems to be racing away as we sit and hope for more improvements.

Cheers!

Q: Hi team,

What are your thoughts about Valent’s earnings? Do you believe a turnaround is possible and would you buy in now or still too risky? Thanks as always.

Q: What are your thoughts on VRX? FDA gives a surprise green light to the drug VYZULTA which was not expected until 2018.
Would you recommend entering into a position on VRX today?